Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with Staphylococcus aureus

Wouthuyzen-Bakker, Marjan; Tornero, Eduard; Morata, Laura; Panday, Prashant V Nannan; Jutte, Paul C.; Bori, Guillem; Kampinga, Greetje A.; Soriano, Álex

doi:10.1016/j.ijantimicag.2017.04.011

Cited by 21 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The favorable blood/bone ratio [11] and the high bioavailability of moxifloxacin and rifampicin also allow a short initial intravenous treatment; median duration was 14 days in our series. The combination of moxifloxacin and rifampicin has already been used in staphylococcal prosthetic joint infection and the success rate was not different than that reported with the levofloxacin-rifampicin combination in a recent retrospective study [12]. In our series, the seven cases of co-infection with S. aureus were associated with favorable outcomes.…”

Section: Discussionsupporting

confidence: 46%

See 1 more Smart Citation

Moxifloxacin-rifampicin combination for the treatment of non-staphylococcal Gram-positive orthopedic implant-related infections

Fily

Jolivet‐Gougeon

Polard

et al. 2019

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 46%

“…However, reduction of moxifloxacin plasma concentration has been reported in patients treated with rifampicin and isoniazid for tuberculosis [13]. The clinical relevance of this interaction is still debated [12,14] and extrapolation to nontuberculosis patients has to be confirmed.…”

Section: Discussionmentioning

confidence: 99%

Moxifloxacin-rifampicin combination for the treatment of non-staphylococcal Gram-positive orthopedic implant-related infections

Fily

Jolivet‐Gougeon

Polard

et al. 2019

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

“…The reduction of serum levels of antibiotics induced by rifampin is not always clinically relevant and depends on the intrinsic activity of the antibiotic, the degree of reduction and the dosage of the co-antibiotic administered. This is supported by the high success rate of moxifloxacin combination therapy [ 26 ], an antibiotic that is also affected by rifampin [ 27 , 28 ]. In concordance with the study of Tornero et al, cotrimoxazole showed the highest treatment failure in our analysis.…”

Section: Discussionmentioning

confidence: 99%

If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study

Beldman

Löwik

Soriano

et al. 2021

Clinical Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Background Rifampin is generally advised in the treatment of acute staphylococcal periprosthetic joint infections (PJI). However, if, when, and how to use rifampinremains a matter of debate. We evaluated the outcome of patients treated with and without rifampin, and analyzed the influence of timing, dose and co-antibiotic. Methods Acute staphylococcal PJIs treated with surgical debridement between 1999 and 2017, and a minimal follow-up of 1 year were evaluated. Treatment failure was defined as the need for any further surgical procedure related to infection, PJI-related death or the need for suppressive antimicrobial treatment. Results A total of 669 patients were analyzed. Treatment failure was 32.2% (131/407) in patients treated with rifampin and 54.2% (142/262) in whom rifampin was withheld (P < 0.001). The most prominent effect of rifampin was observed in knees (treatment failure 28.6% versus 63.9%, respectively, P < 0.001). The use of rifampin was an independent predictor of treatment success in the multi-variate analysis (OR 0.30, 95% CI 0.20 – 0.45). In the rifampin group, the use of a co-antibiotic other than a fluoroquinolone or clindamycin (OR 10.1, 95% CI 5.65 – 18.2) and the start of rifampin within 5 days after surgical debridement (OR 1.96, 95% CI 1.08 – 3.65) were predictors of treatment failure. The dosing of rifampin had no effect on outcome. Conclusions Our data supports the use of rifampin in acute staphylococcal PJIs treated with surgical debridement, particularly in knees. Immediate start of rifampin after surgical debridement should probably be discouraged, but requires further investigation.

show abstract

“…However, in these cases, rifampin should not be administered. In several observational studies over the following years, the success rate in patients with PJI treated with a defined duration of rifampin combination therapy ranged between 55% and 100% (61,64,66,(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80)(81)(82)(83)(84). This wide range still triggers the discussion on the divergence of outcome results.…”

Section: Rifampin In Staphylococcal Pji In Humansmentioning

confidence: 99%

“…However, since levofloxacin has a low MIC against staphylococci, many observational studies have been performed with levofloxacin as combination partner (72,79,96). Recently, Wouthuyzen-Bakker et al (74) showed that the success rates in patients with early acute PJI caused by MSSA and treated with DAIR were similar with moxifloxacin/rifampin and levofloxacin/rifampin (89% versus 87.5%).…”

Section: Mode Of Administration and Rifampin Dose And Combination Agementioning

confidence: 99%

Role of Rifampin against Staphylococcal Biofilm Infections In Vitro , in Animal Models, and in Orthopedic-Device-Related Infections

Zimmerli

Sendi

2019

Antimicrob Agents Chemother

158

112

View full text Add to dashboard Cite

Rifampin has been used as an agent in combination therapy in orthopedic device-related infections (ODRI) for almost three decades. The aim of this review is to provide data regarding the role of rifampin against biofilm infection in vitro, in animal models, and in clinical ODRI. Available data are gathered in order to present the rational use of rifampin combinations in patients with periprosthetic joint infection (PJI). The role of rifampin is well defined in patients with PJI and is indicated in those who fulfill the Infectious Diseases Society of America criteria for debridement and implant retention or one-stage exchange. It should be used with care because of the danger of rapid emergence of resistance. Potential drug interactions should be considered.

show abstract

Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with Staphylococcus aureus

Cited by 21 publications

References 24 publications

Moxifloxacin-rifampicin combination for the treatment of non-staphylococcal Gram-positive orthopedic implant-related infections

Moxifloxacin-rifampicin combination for the treatment of non-staphylococcal Gram-positive orthopedic implant-related infections

If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study

Role of Rifampin against Staphylococcal Biofilm Infections In Vitro , in Animal Models, and in Orthopedic-Device-Related Infections

Contact Info

Product

Resources

About